Overview Financials News + Filings IR Vault Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Quarterly results
CC transcript
Consulting agrmnt
Appointed COO
|
|
CEPHALON INC (CEPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/14/2011 |
8-K
| Quarterly results |
| 10/11/2011 |
8-K
| Form 8-K - Current report |
| 09/30/2011 |
8-K
| Other Events |
| 09/26/2011 |
8-K
| Other Events |
| 08/22/2011 |
8-K
| Form 8-K - Current report |
| 08/02/2011 |
8-K
| Quarterly results |
| 07/21/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/14/2011 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 06/29/2011 |
8-K
| Form 8-K - Current report |
| 05/24/2011 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Eighth Amendment to the Credit Agreement among Cephalon, Inc., the lenders named therein, JPMorgan Chase Bank, N.A., as administrative agent, Deutsche Bank Securities Inc. and Bank of America N.A., as co-syndication agents, Wachovia Bank, N.A. and Barclays Bank plc, as co-documentation agents, and J.P. Morgan Securities Inc., Deutsche Bank Securities Inc. and Banc of America Securities LLC, as joint bookrunners and joint lead arrangers",
"Cephalon to declare recommended ChemGenex Offers unconditional on reaching 90% under each Offer 20 May 2011 — Cephalon CXS Holdings Pty Ltd today provided an update on the status of its cash offers for ChemGenex Shares and ChemGenex Listed Options. The aggregate of the Cephalon Group's existing shareholding in ChemGenex, acceptances of the Share Offer and acceptances in the Institutional Acceptance Facility now represents approximately 78.01% of all ChemGenex Shares on issue. Cephalon also has a relevant interest in 86.40% of all ChemGenex Listed Options on issue. Cephalon has confirmed that, if:",
"Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation" |
|
| 05/16/2011 |
8-K
| Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Financial Statements and Exh... |
| 05/13/2011 |
8-K
| Other Events |
| 05/03/2011 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 05/02/2011 |
8-K
| Form 8-K - Current report |
| 04/11/2011 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/07/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 03/30/2011 |
8-K
| Form 8-K - Current report |
| 03/25/2011 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Cephalon Announces Definitive Agreement to Acquire Gemin X",
"Cephalon Wins FENTORA Patent Suit Against Watson FRAZER, Pa., March 24, 2011 — Cephalon, Inc. announced that today the United States District Court in Delaware upheld the validity of Cephalon's U.S. Patent Number 6,264,981 patent and found that Watson Pharmaceuticals, Inc's proposed generic version of FENTORA® infringes that patent. The Court also denied Watson's motion to vacate a previously entered injunction preventing Watson from marketing its product. “We are pleased with the court's ruling upholding the validity of our patent, as well as its finding that Watson's product infringes that patent,” said Jerry Pappert, Executive Vice President and General Counsel of Cephalon. This decision pertained to patent litigation brought by Cephalon and its wholly-owned subsidiary CIMA Labs, Inc. a..." |
|
| 03/16/2011 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Fourth Amended and Restated Bylaws",
"Form of Indemnification Agreement by and between Cephalon, Inc. and the directors and executive officers listed therein of Cephalon, Inc",
"Executive Severance Agreement by and between Cephalon, Inc. and J. Kevin Buchi",
"Form of Executive Severance Agreement by and between Cephalon, Inc. and the executive officers listed therein",
"Amendment to Employment Contract by and between Cephalon, Inc. and Alain Aragues",
"Cephalon Appoints Charles J. Homcy, M.D. to Board of Directors",
"Court Rules on First Set of Patents in FENTORA Litigation FRAZER, Pa. — On March 11, 2011, the United States District Court for the District of Delaware issued a decision as to a portion of the patent litigation brought by Cephalon Inc., and its wholly-owned subsidiary CIMA Labs, Inc., against Watson Pharmaceuticals, Inc., and its wholly-owned subsidiary Watson Laboratories, Inc., pertaining to Cephalon's FENTORA® fentanyl buccal tablet product. The Court ruled in Watson's favor on two of the three patents at issue in the case. The Court has yet to rule on the third patent. “This decision does not resolve the litigation,” said Jerry Pappert, Cephalon's Executive Vice President and General Counsel. “We remain confident in the strength of our claims with respect to the third patent. In the i..." |
|
| 02/16/2011 |
8-K
| Form 8-K - Current report |
| 02/10/2011 |
8-K
| Form 8-K - Current report |
| 02/09/2011 |
8-K
| Form 8-K - Current report |
| 01/10/2011 |
8-K
| Form 8-K - Current report |
| 12/28/2010 |
8-K
| Form 8-K - Current report |
| 12/23/2010 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors",
"Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D. Frazer, PA — December 17, 2010 — Cephalon, Inc. is sad to announce today that its founder, Chairman and Chief Executive Officer, Frank Baldino, Jr., Ph.D. passed away Thursday evening, December 16, 2010. A pioneer in the biotechnology industry, he was an inspirational leader who will be sorely missed. The Cephalon organization mourns his passing and extends its sympathies to the entire Baldino family. Media Contacts: Cephalon: Fritz Bittenbender Vice President, Public Affairs T: 610-883-5855 C: 610-457-7041" |
|
| 12/10/2010 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Sixth Amendment to the Credit Agreement among Cephalon, Inc., the lenders named therein, JPMorgan Chase Bank, N.A., as administrative agent, Deutsche Bank Securities Inc. and Bank of America N.A., as co-syndication agents, Wachovia Bank, N.A. and Barclays Bank plc, as co-documentation agents, and J.P. Morgan Securities Inc., Deutsche Bank Securities Inc. and Banc of America Securities LLC, as joint bookrunners and joint lead arrangers",
"Cephalon and Mesoblast Enter Into Strategic Alliance to Develop and Commercialize Novel Therapeutic Products for Regenerative Medicine",
"Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely" |
|
| 11/19/2010 |
8-K
| Other Events |
| 10/28/2010 |
8-K
| Form 8-K - Current report |
| 10/27/2010 |
8-K
| Other Events, Financial Statements and Exhibits |
| 10/22/2010 |
8-K
| Form 8-K - Current report |
| 10/21/2010 |
8-K
| Form 8-K - Current report |
| 10/12/2010 |
8-K
| Form 8-K - Current report |
| 08/25/2010 |
8-K
| Form 8-K - Current report |
| 08/19/2010 |
8-K
| Form 8-K - Current report |
|
|
|